The Impact of a Pharmacist-Led Deprescribing Program on the Medication-Related Burden among Iraqi Hemodialysis Patients
DOI:
https://doi.org/10.31351/vol34iss1pp49-58Keywords:
chronic kidney disease, hemodialysis, deprescribing, medication-related burden, Iraq.Abstract
Hemodialysis (HD) Patients have one of the most significant polypharmacy and medication burdens of any patient population. This may be partially attributed to the high number of medications prescribed to manage chronic kidney disease (CKD) and comorbid conditions. Adding to this high volume of medications, medication regimen complexity can increase based on instructions for use, frequency of dosing, and complicated dosage formulations that may be harder to use. One way to combat polypharmacy and inappropriate medication use is through medication deprescribing. The aim of this study was to assess the impact of implementing a pharmacist-led deprescribing program on the medication-related burden among HD patients. A prospective interventional, one-group, follow-up study was conducted at Wasit Center for Hemodialysis, Wasit Governorate, Iraq. Medication reconciliation followed by medication review based on the deprescribing program was done for all eligible patients, and the patients were monitored for three months for any possible complications. Two hundred and seventy patients were screened for eligibility, and only one hundred and eighteen patients were enrolled in the deprescribing program. The median age was 51.5 years (Interquartile range; IQR 39–62), 56.8% were males, and hypertension was the most common etiology for their CKD; 78% had comorbidities other than hypertension and CKD. After deprescription, there was a significant reduction in the number of medications from 6.0 (IQR 4.75–7.0) to 4.0 (IQR 3.0-5.0) (p < .001) and a reduction in the number of pills from 7.0 (6.0–9.0) to 5.0 (4.0–6.0) (p < .001). Medication-related burden assessed using the Arabic version of LMQ-3 also showed a significant reduction from 125.00 (IQR 111.75-138.0) to 114.0 (IQR 104.0-123.0) (p < .005). A pharmacist-led deprescribing program successfully reduced the number of medications and daily pills prescribed while simultaneously improving medication-related burden among hemodialysis patients.
How to Cite
Publication Dates
Received
Revised
Accepted
Published Online First
References
Tran VT, Barnes C, Montori VM, Falissard B, Ravaud P. Taxonomy of the burden of treatment: a multi-country web-based qualitative study of patients with chronic conditions. BMC Med. 2015;13(1):115.
Bekalu AF, Yenit MK, Tekile MT, Birarra MK. Medication-related burden and associated factors among diabetes mellitus patients at Felege Hiwot Comprehensive Specialized Hospital in northwest Ethiopia. Front Clin Diabetes Healthc. 2022;3(September):1–9.
Gerardi S, Sperlea D, Levy SOL, Bondurant-David K, Dang S, David PM, et al. Implementation of targeted deprescribing of potentially inappropriate medications in patients on hemodialysis. Am J Health Syst Pharm. 2022;79(4):S128–35.
Mohottige D, Manley HJ, Hall RK. Less is More: Deprescribing Medications in Older Adults with Kidney Disease: A Review. Kidney360. 2021;2(9):1510–22.
Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017 Oct;17(1):230.
Manski-Nankervis JA, McMorrow R, Nelson C, Jesudason S, Sluggett JK. Prescribing and deprescribing in chronic kidney disease. Aust J Gen Pract. 2021;50(4):183–7.
Isenor JE, Bai I, Cormier R, Helwig M, Reeve E, Whelan AM, et al. Deprescribing interventions in primary health care mapped to the Behaviour Change Wheel: A scoping review. Res Soc Adm Pharm. 2021;17(7):1229–41.
Hernández-Prats C, López-Pintor E, Lumbreras B. Pharmacist-led intervention on the reduction of inappropriate medication use in patients with heart failure: A systematic review of randomized trials and non-randomized intervention studies. Res Soc Adm Pharm. 2022;18(5):2748–56.
Battistella M, Ng P. Addressing polypharmacy in outpatient dialysis units. Clin J Am Soc Nephrol. 2021;16(1):144–6.
Bondurant-David K, Dang S, Levy S, Sperlea D, Vanier MC, Gerardi S, et al. Issues with deprescribing in haemodialysis: a qualitative study of patient and provider experiences. Int J Pharm Pract. 2020;28(6):635–42.
Study T, Hospitals BT, City B, Teaching B. Assessment Of Hemodialysis Patient ’ s Compliance To The Treatment And Follow Up In Baghdad Teaching Hospitals. 2013;1–10.
Abdul-Jabbar MA, Kadhim DJ. Adherence to Different Treatment Modalities among Patients on Maintenance Hemodialysis. Iraqi J Pharm Sci. 2022;31(1):95–101.
Kadhim Jwad R, Jabbar Kadhim D, Hadi Munshed Alosami M, G. Shareef L. Medication-related burden among Iraqi patients with rheumatoid arthritis: An observational study. F1000Research. 2022;11:1–10.
Kadhim Abbas H, Jabbar Kadhim D, Isho Gorial F, Shareef LG. Assessment of medication-related burden among a sample of Iraqi patients with systemic lupus erythematosus and its relationship with disease activity: a cross-sectional study. F1000Research. 2022;11:1–15.
Jamal Noori A, Jabbar Kadhim D, Abdulhasan Al-Hilal M. Medication-related burden among patients with diabetes mellitus and its relation to diabetic control parameters: an observational study. F1000Research. 2022;11:1–14.
Zidan A, Awaisu A, El-Hajj MS, Al-Abdulla SA, Figueroa DCR, Kheir N. Medication-Related Burden among Patients with Chronic Disease Conditions: Perspectives of Patients Attending Non-Communicable Disease Clinics in a Primary Healthcare Setting in Qatar. Pharm (Basel, Switzerland). 2018 Aug;6(3).
Katusiime B. Development and validation of the Living with Medicines Questionnaire; a generic measure of patients experiences of medicine use and associated burden. Vol. 2. University of Kent, The University of Greenwich; 2017.
Sibbel S, Walker AG, Colson C, Tentori F, Brunelli SM, Flythe J. Association of continuation of loop diuretics at hemodialysis initiation with clinical outcomes. Clin J Am Soc Nephrol. 2019;14(1):95–102.
Tang X, Chen L, Chen W, Li P, Zhang L, Fu P. Effects of diuretics on intradialytic hypotension in maintenance dialysis patients: a systematic review and meta-analysis. Int Urol Nephrol [Internet]. 2021;53(9):1911–21. Available from: https://doi.org/10.1007/s11255-021-02805-x
Parker K, Wong J. Is polypharmacy an increasing burden in chronic kidney disease? the German experience. Clin Kidney J. 2019;12(5):659–62.
Mathieu C, Ásbjörnsdóttir B, Bajaj HS, Lane W, Matos ALSA, Murthy S, et al. Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial. Lancet (London, England). 2023 Jun;401(10392):1929–40.
S. Berns J, D. Glickman J. Management of Hyperglycemia in Patients with Type 2 Diabetes and Pre-dialysis Chronic Kidney Disease or End-stage Renal Disease. In: Ted. W. Post, editor. UpToDate in Waltham, MA; 2023. Available from: http://www.uptodate.com
Diabetes and Hemodialysis. Indian J Nephrol. 2020 Jul;30(Suppl 1):S73.
Zhang Y, Deng D, Zhang R, Yi J, Dong J, Sha L. Relationship between Proton Pump Inhibitors and Adverse Effects in Hemodialysis Patients: A Systematic Review and Meta-Analysis. Kidney Blood Press Res [Internet]. 2022 Jul 25;47(9):545–55. Available from: https://doi.org/10.1159/000526122
Parkman HP. Chapter 24 - Prokinetic agents for gastroparesis. In: McCallum RW, Parkman HPBTG, editors. Academic Press; 2021. p. 323–39.
Murea M, Tucker BM. The physiology of uric acid and the impact of end-stage kidney disease and dialysis. Semin Dial. 2019 Jan;32(1):47–57.
Rohn B, Jansing W, Seibert FS, Pfab T, Cinkilic O, Paßfall J, et al. Association of hyperuricemia and serum uric acid lowering therapy with mortality in hemodialysis patients. Ren Fail. 2020;42(1):1067–75.
Hurst FP, Neff RT, Falta EM, Jindal RM, Lentine KL, Swanson JS, et al. Incidence, predictors, and associated outcomes of prostatism after kidney transplantation. Clin J Am Soc Nephrol. 2009 Feb;4(2):329–36.
Berns JS. Treatment of Iron Deficiency Anaemia in Dialysis Patients. In: Ted. W. Post, editor. UpToDate in Waltham, MA; 2023. Available from: http;//www.uptodate.com
Ganz T, Nemeth E. Iron Balance and the Role of Hepcidin in Chronic Kidney Disease. Semin Nephrol. 2016 Mar;36(2):87–93.
Baryakova TH, Pogostin BH, Langer R, McHugh KJ. Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems. Nat Rev Drug Discov. 2023 May 27;22(5):387–409.
Al-mansouri A, Al-Ali FS, Hamad AI, Mohamed Ibrahim MI, Kheir N, Ibrahim RA, et al. Assessment of treatment burden and its impact on quality of life in dialysis-dependent and pre-dialysis chronic kidney disease patients. Res Soc Adm Pharm. 2021;17(11):1937–44.
George JS, Joseph R, Thomas ETA, John GP, Siby A, Nair MM. Active deprescribing program in chronic kidney disease patients undergoing haemodialysis. Nephrology. 2021 Nov 15;26(11):890–7.
.Dipl AAA, Fibms-fm EA kaseer, Ffph JKA diwan F. Hepatitis C Virus Infection among Patients in Hemodialysis Unit at Baghdad Teaching Hospital. 2021;67(11):51–6.
Dhaidan FA. Prevalence of end stage renal disease and associated conditions in hemodialysis Iraqi patients. Int J Res Med Sci. 2018;6(5):1515.
Talib AF, Mudhafar ZN. The role of clinical pharmacist in reducing drug related problems in hemodialysis patients. Iraqi J Pharm Sci. 2021;29(2):223–30.
Aggarwal P, Woolford SJ, Patel HP. Multi-Morbidity and Polypharmacy in Older People: Challenges and Opportunities for Clinical Practice. Geriatr (Basel, Switzerland). 2020 Oct;5(4).
Al-mansouri A, Hamad AI, Al-Ali FS, Ibrahim MIM, Kheir N, Al-Ziftawi NH, et al. Pill-burden and its association with treatment burden among patients with advanced stages of chronic kidney disease. Saudi Pharm J. 2023;31(5):678–86.
Fissell R, Robinson B. Should high-dose oral diuretics be used to increase urine output in patients on chronic peritoneal and hemodialysis? Semin Dial. 2011;24(4):366–8.
Schoenfeld AJ, Grady D. Adverse Effects Associated With Proton Pump Inhibitors. JAMA Intern Med. 2016 Feb 1;176(2):172–4.
Ago R, Shindo T, Banshodani M, Shintaku S, Moriishi M, Masaki T, et al. Hypomagnesemia as a predictor of mortality in hemodialysis patients and the role of proton pump inhibitors: A cross-sectional, 1-year, retrospective cohort study. Hemodial Int. 2016 Oct;20(4):580–8.
Hu X, Rong S, Wang Q, Sun T, Bao W, Chen L, et al. Association between plasma uric acid and insulin resistance in type 2 diabetes: A Mendelian randomization analysis. Diabetes Res Clin Pract [Internet]. 2021;171:108542. Available from: https://www.sciencedirect.com/science/article/pii/S0168822720307993
Beberashvili I, Erlich A, Azar A, Sinuani I, Feldman L, Gorelik O, et al. Longitudinal study of serum uric acid, nutritional status, and mortality in maintenance hemodialysis patients. Clin J Am Soc Nephrol. 2016;11(6):1015–23.
Albisinni S, Biaou I, Marcelis Q, Aoun F, De Nunzio C, Roumeguère T. New medical treatments for lower urinary tract symptoms due to benign prostatic hyperplasia and future perspectives. BMC Urol. 2016;16(1):58.
Mercadal L, Metzger M, Haymann JP, Thervet E, Boffa JJ, Flamant M, et al. The relation of hepcidin to iron disorders, inflammation and hemoglobin in chronic kidney disease. PLoS One. 2014;9(6):e99781.
Gutiérrez OM. Treatment of Iron Deficiency Anemia in CKD and End-Stage Kidney Disease. Kidney Int Reports. 2021;6(9):2261–9.
Agrawal S, Sonawane S, Kumar S, Acharya S, Gaidhane SA, Wanjari A, et al. Efficacy of Oral Versus Injectable Iron in Patients With Chronic Kidney Disease: A Two-Year Cross-Sectional Study Conducted at a Rural Teaching Hospital. Cureus. 2022;14(Iv).
Wei Q, Zhou J, Li H, Wang L, Wu Y, Ma A, et al. Medication adherence with fixed-dose versus free-equivalent combination therapies: Systematic review and meta-analysis. Front Pharmacol. 2023;14(March):1–10.
Rochon Paula A. Drug prescribing for older adults. In: Ted. W. Post, editor. UpToDate in Waltham, MA; 2023. Available from: http://www.uptodate.com
Wexler DJ. Insulin therapy in type 2 diabetes mellitus. In: Post TW, editor. UpToDate in Waltham, MA; 2023. Available from: http://www.uptodate.com.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Iraqi Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
